ntq5082
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Aug 31, 2024 (NCT06558656)
Timeline
Indications
Mechanism of action
- Complement factor BINHIBITOR
CFB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07177872 | Phase 3 | Jun 30, 2026 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT07177859 | Phase 3 | Nov 30, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06982040 | Phase 2 | May 31, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06764303 | Phase 2 | Jan 31, 2025 | Chinese Academy of Medical Sciences, Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Zhejiang University |
| NCT06560593 | Phase 1 | Aug 31, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06558656 | Phase 1 | Aug 31, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 6 | 6 | 3 | 2024 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1